|
.
|
|
| HSR |
Table HSR-0. References for needle and syringe programme information
|
table |
| HSR |
Table HSR-1. Number of syringe provision outlets and number of syringes (in thousands) exchanged, distributed or sold in 2005
|
table |
| HSR |
Table HSR-2. Year of introduction of needle and syringe programmes and types of programmes available in 2005
|
table |
| HSR |
Table HSR-3. Number of non-pharmacy needle and syringe programme points and number of syringes exchanged, distributed or sold 2002-2005
|
table |
| HSR |
Table HSR-4. Total number of pharmacy-based needle and syringe programmes and number of syringes exchanged or distributed 2002-2005
|
table |
| HSR |
Table HSR-5. Number of syringe vending machines and number of syringes distributed or sold 2002-2005
|
table |
| HSR |
Table HSR-6. Legal framework and practice of substitution treatment initiation
|
table |
| HSR |
Table HSR-7. Estimated number of clients in methadone treatment and of clients receiving any opioid substitution in EU-27 and Norway, 2003 and 2005
|
table |
| HSR |
Table HSR-8. Year of introduction of methadone maintenance treatment (MMT), high-dosage buprenorphine treatment (HDBT) and heroin-assisted treatment, including trials
|
table |
| HSR |
Table HSR-9. Consumption of methadone (kg) in 29 European countries, in the Unites States of America and total consumption worldwide, 1992 to 2005
|
table |
| HSR |
Table HSR-10. National substitution registries and other sources of data on substitution clients
|
table |
| HSR |
Table HSR-11. Estimated number of clients in methadone treatment in EU countries and Norway, 1993 - 2005
|
table |
| HSR |
Figure HSR-1. Year of introduction of methadone maintenance and high dosage buprenorphine treatmentin 26 EU countries and Norway
|
figure |
| HSR |
Figure HSR-3. Number of opioid maintenance treatment clients as rate per 100 of the estimated number of problem opioid users, 2004 and 2005
|
figure |
| HSR |
Figure HSR-4. Estimated number of clients receiving opioid substitution treatment each year in EU-15, 1993-2005
|
figure |
| SZR |
Table SZR-1. Number of cannabis resin seizures, 1995 to 2005
|
table |
| SZR |
Table SZR-2. Quantities (kg) of cannabis resin seized, 1995 to 2005
|
table |
| SZR |
Table SZR-3. Number of herbal cannabis seizures, 1995 to 2005
|
table |
| SZR |
Table SZR-4. Quantities (kg) of herbal cannabis seized, 1995 to 2005
|
table |
| SZR |
Table SZR-5. Number of seizures of cannabis plants, 1995 to 2005
|
table |
| SZR |
Table SZR-6. Quantities (number of plants) of cannabis plants seized, 1995 to 2005
|
table |
| SZR |
Table SZR-7. Number of heroin seizures 1995 to 2005
|
table |
| SZR |
Table SZR-8. Quantities (kg) of heroin seized 1995 to 2005
|
table |
| SZR |
Table SZR-9. Number of cocaine seizures 1995 to 2005
|
table |
| SZR |
Table SZR-10. Quantities (kg) of cocaine seized 1995 to 2005
|
table |
| SZR |
Table SZR-11. Number of amphetamine seizures 1995 to 2005
|
table |
| SZR |
Table SZR-12. Quantities (kg) of amphetamine seized 1995 to 2005
|
table |
| SZR |
Table SZR-13. Number of ecstasy seizures 1995 to 2005
|
table |
| SZR |
Table SZR-14. Quantities (tablets) of ecstasy seized 1995 to 2005
|
table |
| SZR |
Table SZR-15. Number of LSD seizures 1995 to 2005
|
table |
| SZR |
Table SZR-16. Quantities (units) of LSD seized 1995 to 2005
|
table |
| SZR |
Table SZR-17. Number of Methamphetamine seizures. 2001 to 2005
|
table |
| SZR |
Table SZR-18. Quantities (kg) of Methamphetamine seized. 2001 to 2005
|
table |
| SZR |
Table SZR-107. Number of heroin seizures 1985 to 2005
|
table |
| SZR |
Table SZR-108. Quantities (kg) of heroin seized 1985 to 2005
|
table |
| SZR |
Table SZR-109. Number of cocaine seizures 1985 to 2005
|
table |
| SZR |
Table SZR-110. Quantities (kg) of cocaine seized 1985 to 2005
|
table |
| SZR |
Table SZR-111. Number of amphetamine seizures 1985 to 2005
|
table |
| SZR |
Table SZR-112. Quantities (kg) of amphetamine seized 1985 to 2005
|
table |
| SZR |
Table SZR-113. Number of ecstasy seizures 1987 to 2005
|
table |
| SZR |
Table SZR-114. Quantities (tablets) of ecstasy seized 1987 to 2005
|
table |
| SZR |
Table SZR-115. Number of LSD seizures 1995 to 2005
|
table |
| SZR |
Table SZR-116. Quantities (units) of LSD seized 1995 to 2005
|
table |
| PPP |
Table PPP-1. Price of cannabis products at retail level, 2005
Part (i) Minimum, maximum, mean and modal (typical) price in euros
|
table |
| PPP |
Table PPP-1. Price of cannabis products at retail level, 2005
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-2. Price of heroin at retail level, 2005
Part (i) Minimum, maximum, mean and modal (typical) price in euros
|
table |
| PPP |
Table PPP-2. Price of heroin at retail level, 2005
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-3. Price of cocaine products at retail level, 2005
Part (i) Minimum, maximum, mean and modal (typical) price in euros
|
table |
| PPP |
Table PPP-3. Price of cocaine products at retail level, 2005
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-4. Price of synthetic drugs at retail level, 2005
Part (i) Minimum, maximum, mean and modal (typical) price in euros
|
table |
| PPP |
Table PPP-4. Price of synthetic drugs at retail level, 2005
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-5. Potency of cannabis products at retail level, 2005
Part (i) Minimum, maximum, mean and modal (typical) potency recorded, measured as percentage of THC content
|
table |
| PPP |
Table PPP-5. Potency of cannabis products at retail level, 2005
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-5. Potency of cannabis products at retail level, 2005
Part (iii) Sampling frame/type of study
|
table |
| PPP |
Table PPP-6. Purity of heroin at retail level, 2005
Part (i) Minimum, maximum, mean and modal (typical) purity recorded (percentage)
|
table |
| PPP |
Table PPP-6. Purity of heroin at retail level, 2005
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-6. Purity of heroin at retail level, 2005
Part (iii) Sampling frame/type of study
|
table |
| PPP |
Table PPP-7. Purity of cocaine products at retail level, 2005
Part (i) Minimum, maximum, mean and modal (typical) purity recorded (percentage)
|
table |
| PPP |
Table PPP-7. Purity of cocaine products at retail level, 2005
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-7. Purity of cocaine products at retail level, 2005
Part (iii) Sampling frame/type of study
|
table |
| PPP |
Table PPP-8. Purity of synthetic drugs at retail level, 2005
Part (i) Minimum, maximum, mean and modal (typical) purity recorded
|
table |
| PPP |
Table PPP-8. Purity of synthetic drugs at retail level, 2005
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-8. Purity of synthetic drugs at retail level, 2005
Part (iii) Sampling frame/type of study
|
table |
| PPP |
Figure PPP-1. Indexed trends in EU retail prices for major drug types, adjusting for inflation, 2000-2005
|
figure |
| GPS |
Table GPS-0. Nationwide surveys among the general population: bibliographic references
|
table |
| GPS |
Table GPS-1. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
Part (i) Lifetime prevalence all adults (percentage)
|
table |
| GPS |
Table GPS-1. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
Part (ii) Survey methods
|
table |
| GPS |
Table GPS-2. Lifetime prevalence of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-3. Last year prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-4. Last year prevalence of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-5. Last month prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-6. Last month prevalence of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-7. Last month prevalence and frequency of use of cannabis among all adults (aged 15 to 64 years old) and young adults (aged 15 to 34 years old) in nationwide surveys among the general population
Part(i) Last month prevalence (percentage)
|
table |
| GPS |
Table GPS-7. Last month prevalence and frequency of use of cannabis among all adults (aged 15 to 64 years old) and young adults (aged 15 to 34 years old) in nationwide surveys among the general population
Part(ii) Frequency of use among all users in last month (percentage)
|
table |
| GPS |
Table GPS-8. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
Part (i) Lifetime prevalence all adults (percentage): last survey available for each Member State
|
table |
| GPS |
Table GPS-8. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
Part (ii) Survey methods: last survey available for each Member State
|
table |
| GPS |
Table GPS-9. Lifetime prevalence (percentage) of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
|
table |
| GPS |
Table GPS-10. Last year prevalence (percentage) of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population: last survey available for each Member State
|
table |
| GPS |
Table GPS-11. Last year prevalence (percentage) of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
|
table |
| GPS |
Table GPS-12. Last month prevalence (percentage) of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population: last survey available for each Member State
|
table |
| GPS |
Table GPS-13. Last month prevalence (percentage) of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
|
table |
| GPS |
Table GPS-14. Lifetime prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-15. Last year prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-16. Last month prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-17. Lifetime prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population. Last survey available for each Member State
|
table |
| GPS |
Table GPS-18. Last year prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population. Last survey available for each Member State
|
table |
| GPS |
Table GPS-19. Last month prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population: last survey available for each Member State
|
table |
| GPS |
Table GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (i) United Kingdom
|
table |
| GPS |
Table GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (ii) Germany
|
table |
| GPS |
Table GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (iii) Spain
|
table |
| GPS |
Table GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (iv) France
|
table |
| GPS |
Table GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (v) Italy
|
table |
| GPS |
Table GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (vi) Netherlands
|
table |
| GPS |
Table GPS-21. Methodological information for nation-wide surveys among the general population
|
table |
| GPS |
Figure GPS-1. Last year prevalence of cannabis among all adults (aged 15 to 64 years old), young adults (aged 15 to 34 years old) and for the 15 to 24 years old age group, measured by national population surveys
|
figure |
| GPS |
Figure GPS-2. Continuation rates of cannabis (last year and last month use among lifetime users) in the general population, as measured by national surveys
|
figure |
| GPS |
Figure GPS-3. Last month prevalence of cannabis among the age group of 15 to 24 years, measured by national surveys
|
figure |
| GPS |
Figure GPS-4. Trends in last year prevalence of cannabis among young adults (aged 15 to 34), measured by national surveys
|
figure |
| GPS |
Figure GPS-5. Last year prevalence of amphetamines among young adults, 15 to 34 and 15 to 24, measured by population surveys
|
figure |
| GPS |
Figure GPS-6. Last year prevalence of amphetamines among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
|
figure |
| GPS |
Figure GPS-7. Last month prevalence of cannabis among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group
|
figure |
| GPS |
Figure GPS-8. Trends in last year use of amphetamines among young adults (aged 15 to 34), measured by population surveys
|
figure |
| GPS |
Figure GPS-9. Last year prevalence of ecstasy among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group
|
figure |
| GPS |
Figure GPS-10. Last year prevalence of cannabis by age group in United Kingdom, measured by national population surveys
|
figure |
| GPS |
Figure GPS-11. Continuation rates of ecstasy (last year and last month use among lifetime users) in the general population, as measured by national surveys
|
figure |
| GPS |
Figure GPS-12. Last year prevalence of cannabis by age group in some Member States, measured by national population surveys – last survey available
Part (i) Last year prevalence in some of the EU-15 Member States
|
figure |
| GPS |
Figure GPS-13. Last year prevalence of cocaine among all young adults (aged 15 to 34 ) by gender, measured by national surveys
|
figure |
| GPS |
Figure GPS-14. Trends in last year prevalence of cocaine among young adults (aged 15 to 34), measured by population surveys
|
figure |
| GPS |
Figure GPS-15. Last year prevalence of cocaine use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
|
figure |
| GPS |
Figure GPS-16. Continuation rates of cocaine (last year and last month use among lifetime users) in the general population, measured by national surveys
|
figure |
| GPS |
Figure GPS-17. Last year prevalence of amphetamines, ecstasy and cocaine among young adults (15 to 34 years)
|
figure |
| GPS |
Figure GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34)
Part (i) Cannabis use – lifetime experience, last year and last month prevalence
|
figure |
| GPS |
Figure GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34)
Part (ii) Cocaine, amphetamines and ecstasy use – lifetime experience, last year and last month prevalence
|
figure |
| GPS |
Figure GPS-19. Comparison of drug use prevalence during last year by different user groups in the general population aged 15 to 34 – data for Spain, 1999
|
figure |
| GPS |
Figure GPS-20. Lifetime and last year prevalence of cocaine use among young adults (aged 15 to 34) in Europe, Canada, Australia and the USA - last survey available for each country
|
figure |
| GPS |
Figure GPS-21. Trends in last year prevalence of ecstasy among young adults (aged 15 to 34), measured by population surveys
|
figure |
| GPS |
Figure GPS-22. Continuation rates of amphetamines (last year and last month use among lifetime users) in the general population, as measured by national surveys
|
figure |
| GPS |
Figure GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
|
figure |
| EYE |
Table EYE-0. School Surveys: Sources
|
table |
| EYE |
Table EYE-1. Recent school surveys (2003-2005): Lifetime prevalence (percentage) of psychoactive substance use among students aged 15-16 years old
|
table |
| EYE |
Table EYE-2. Recent school surveys (2003-2005): lifetime percentage prevalence (LTP) of psychoactive substance use and last month prevalence (LMP) of cannabis among students aged 17 to 18 years
|
table |
| EYE |
Table EYE-3. School surveys: percentage lifetime prevalence of psychoactive substance use among students aged 15-16 years
|
table |
| EYE |
Table EYE-4. ESPAD 2003 school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15-16 years
Part (i) Females
|
table |
| EYE |
Table EYE-4. ESPAD 2003 school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15-16 years
Part (ii) Males
|
table |
| EYE |
Table EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15-16 years
Part (i) All students
|
table |
| EYE |
Table EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15-16 years
Part (ii) Males
|
table |
| EYE |
Table EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15-16 years
Part (iii) Females
|
table |
| EYE |
Table EYE-6. All ESPAD school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15-16 years
Part (i) Females
|
table |
| EYE |
Table EYE-6. All ESPAD school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15-16 years
Part (ii) Males
|
table |
| EYE |
Table EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15-16 years
Part (i) All students
|
table |
| EYE |
Table EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15-16 years
Part (ii) Males
|
table |
| EYE |
Table EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15-16 years
Part (iii) Females
|
table |
| EYE |
Figure EYE-1. Drug use among minors
Part (i) Distribution of frequency of cannabis use sessions (percentage) according to age at first use among French population aged 17 years old who have ever used cannabis
|
figure |
| EYE |
Figure EYE-1. Drug use among minors
Part (ii) Changes between 1995 and 2003 in recalled use of cannabis at or before age 13 (percentage points) as reported by 15- to 16-year-old school students.
|
figure |
| EYE |
Figure EYE-1. Drug use among minors
Part (iii) Comparison of LTP (percentage) for inhalants/volatile substances between three different school student age groups in 3 countries
|
figure |
| EYE |
Figure EYE-2. Cocaine use among young people
Part (i) Comparison of lifetime prevalence of cocaine use with perceived risk (percentage) among 15- to 16-year-old school students in 2003.
|
figure |
| EYE |
Figure EYE-2. Cocaine use among young people
art (ii) Comparison of lifetime prevalence of cocaine use (percentage) and perceived availability among 15- to 16-year-old school students, 2003.
|
figure |
| EYE |
Figure EYE-2. Cocaine use among young people
Part (iii) Comparison of LTP (percentage) for inhalants/volatile substances between three different school student age groups in 3 countries
|
figure |
| PDU |
Table PDU-0. Prevalence of problem drug use at national and subnational level: bibliographic references
|
table |
| PDU |
Table PDU-1. Prevalence of problem drug use at national level: summary table, 2001-2005, rate per 1000 aged 15-64
Part (i) Overall problem drug use
|
table |
| PDU |
Table PDU-1. Prevalence of problem drug use at national level: summary table, 2001-2005, rate per 1000 aged 15-64
Part (ii) Injecting drug use
|
table |
| PDU |
Table PDU-2. Prevalence of problem drug use at national level - full listing of studies
Part (i) Problem drug use
|
table |
| PDU |
Table PDU-2. Prevalence of problem drug use at national level - full listing of studies
Part (ii) Injecting drug use
|
table |
| PDU |
Table PDU-3. Prevalence of problem drug use at subnational level - full list of studies
Part (i) Problem drug users
|
table |
| PDU |
Table PDU-3. Prevalence of problem drug use at subnational level - full list of studies
Part (ii) Injecting drug users
|
table |
| PDU |
Table PDU-4. Trends in injecting drug use - percentage current injecting among all clients entering treatment for primary drug heroin, 2001 to 2005
|
table |
| PDU |
Figure PDU-1. Estimates of the prevalence of problem drug use (rate per 1000 population aged 15 to 64), studies from 2001 to 2005
Part (i) Estimates of overall PDU
|
figure |
| PDU |
Figure PDU-1. Estimates of the prevalence of problem drug use (rate per 1000 population aged 15 to 64), studies from 2001 to 2005
Part (ii) Estimates for problem opioid use
|
figure |
| PDU |
Figure PDU-2. Estimates of the prevalence of injecting drug use (rate per 1000 population aged 15 to 64), studies from 2001 to 2005
|
figure |
| PDU |
Figure PDU-3. Percentage of new and of young injectors in samples of injecting drug users tested for HIV or HCV, studies from 2003 to 2005
|
figure |
| PDU |
Figure PDU-4. Estimated trends in the prevalence of overall problem drug use 2001 to 2005 (rate per 1000 population aged 15 to 64): Combined estimates per country
|
figure |
| DUP |
Table DUP-0. Prevalence of drug use among prisoners - Sources and bibliographic references
|
table |
| DUP |
Table DUP-1. Prevalence of lifetime drug use among prisoners, 1995-2006
|
table |
| DUP |
Table DUP-2. Prevalence of lifetime injecting drug use among prisoners, 1995-2006
|
table |
| DUP |
Table DUP-3. Prevalence of drug use within prison among prisoners, 1995-2006
|
table |
| DUP |
Table DUP-4. Prevalence of injecting drug use within prison among prisoners, 1995-2006
|
table |
| DUP |
Table DUP-5. Prevalence (percentage) of drug use among prisoners in EU member states and Norway - full listing of studies
|
table |
| DUP |
Figure DUP-1. Studies of lifetime prevalence of use of various drugs among prisoners in some EU Member States, 1999 to 2006
|
figure |
| INF |
Table INF-0. Bibliographic references
|
table |
| INF |
Table INF-1. Prevalence of HIV infection among injecting drug users in the EU, 2005 or most recent year available - Summary table by country
|
table |
| INF |
Table INF-2. Prevalence of HCV antibody among injecting drug users in the EU, 2005 or most recent year available - Summary table by country
|
table |
| INF |
Table INF-3. Prevalence of markers for HBV infection among injecting drug users in the EU, 2005 or most recent year available - Summary table by country
|
table |
| INF |
Table INF-4. HIV infections newly diagnosed in injecting drug users, by year of report from 1992 to 2005, (a) cases per million population and (b) number of cases
|
table |
| INF |
Table INF-5. Notified cases of hepatitis C infection among injecting drug users in the EU: number of IDU cases and percentage of IDUs amongst all cases with known risk factor
Part (i) Notifications of hepatitis C related to IDU, 1992 to 2005
|
table |
| INF |
Table INF-5. Notified cases of hepatitis C infection among injecting drug users in the EU: number of IDUs and percentage of IDUs amongst all cases with known risk factor
Part (ii) Notes and comments, 1992 to 2005
|
table |
| INF |
Table INF-6. Notified cases of hepatitis B infection among injecting drug users in the EU: number of IDU cases and percentage of IDUs amongst all notified cases with known risk factor
Part (i) Notifications hepatitis B related to IDU, 1992 to 2005
|
table |
| INF |
Table INF-6. Notified cases of hepatitis B infection among injecting drug users in the EU: number of IDUs and percentage of IDUs amongst all notified cases having a known risk factor
Part (ii) Notes and comments, 1992 to 2005
|
table |
| INF |
Table INF-7. Incidence studies of hepatitis C virus infection among injecting drug users in the EU
|
table |
| INF |
Table INF-8. Prevalence of HIV infection (percentage) among injecting drug users - Data, 1991 to 2006
|
table |
| INF |
Table INF-9. Prevalence of HIV infection (percentage) among injecting drug users under age 25 - Data, 1991 to 2005
|
table |
| INF |
Table INF-10. Prevalence of HIV infection (percentage) among new injecting drug users (injecting less than 2 years) - Data, 1991 to 2005
|
table |
| INF |
Table INF-11. Prevalence of hepatitis C infection (percentage) among injecting drug users - Data, 1991 to 2005
|
table |
| INF |
Table INF-12. Prevalence of hepatitis C infection (percentage) among injecting drug users under age 25 - Data, 1991 to 2005
|
table |
| INF |
Table INF-13. Prevalence of hepatitis C infection (percentage) among new injecting drug users (injecting less than 2 years) - Data, 1991 to 2005
|
table |
| INF |
Table INF-14. Prevalence of current hepatitis B infection (percentage with HBsAg) among injecting drug users - Data, 1991 to 2005
|
table |
| INF |
Table INF-15. Prevalence of antibodies against hepatitis B virus (percentage) among injecting drug users - Data, 1991 to 2005
|
table |
| INF |
Table INF-16. Estimated HIV prevalence among injecting drug users - selected country-specific studies
|
table |
| INF |
Figure INF-1. AIDS incidence by year of diagnosis among injecting drug users by country, 1996 to 2005
|
figure |
| INF |
Figure INF-2. HIV infections newly diagnosed in injecting drug users in the most severely affected EU countries, Russian Federation and Ukraine, by year of report 1996-2005, cases per million population
|
figure |
| INF |
Figure INF-3. HIV prevalence among injecting drug users – studies with national and subnational coverage
Part (i) All injecting drug users, 2004 - 2005
|
figure |
| INF |
Figure INF-3. HIV prevalence among injecting drug users – studies with national and subnational coverage
Part (ii) Young injecting drug users (aged under 25), 2004 - 2005
|
figure |
| INF |
Figure INF-4. Trends in HIV prevalence among injecting drug users estimated from national and sub-national samples, 2001 to 2005
|
figure |
| INF |
Figure INF-6. Estimated HCV antibody prevalence among injecting drug users – studies with national and subnational coverage
Part (i) All injecting drug users, 2004 - 2005
|
figure |
| INF |
Figure INF-6. Estimated HCV antibody prevalence among injecting drug users – studies with national and subnational coverage
Part (ii) Young injecting drug users (aged under 25), 2004 - 2005
|
figure |
| INF |
Figure INF-7. Trends in HCV antibody prevalence in national and subnational samples of injecting drug users, 2001 to 2005
|
figure |
| INF |
Figure INF-8. Notified cases of hepatitis C related to injecting drug use: proportion injecting drug users among all cases with risk factor information, 2001 to 2005
|
figure |
| INF |
Figure INF-9. Prevalence of markers of HBV infection estimated among national and subnational samples of injecting drug users 2004 to 2005, where data are available
Part (i) Percentage positive for ever infected (aHBc)
|
figure |
| INF |
Figure INF-9. Prevalence of markers of HBV infection estimated among national and subnational samples of injecting drug users 2004 to 2005, where data are available
Part (ii) Percentage positive for current infection (HBsAg)
|
figure |
| INF |
Figure INF-11. Notified cases of hepatitis B in injecting drug users: proportion injecting drug users among hepatitis B notifications with risk factor information, 2001 to 2005
|
figure |
| DRD |
Table DRD-0. Drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions, sources and bibliographic references
|
table |
| DRD |
Table DRD-1. Summary of characteristics of the deceased in drug-related deaths according to national definitions
Part (i) 2005 or last year with available information (demographic characteristics)
|
table |
| DRD |
Table DRD-1. Summary of characteristics of the deceased in drug-related deaths according to national definitions
Part (ii) 2005 or last year with available information (toxicology and numbers by selected age groups)
|
table |
| DRD |
Table DRD-1. Summary of characteristics of the deceased in drug-related deaths according to national definitions
Part (iii) 1990 or closest year with available information
|
table |
| DRD |
Table DRD-2. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions
Part (i) Total drug-related deaths, 1990 to 2005
|
table |
| DRD |
Table DRD-2. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions
Part (ii) Male drug-related deaths, 1990 to 2005
|
table |
| DRD |
Table DRD-2. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions
Part (iii) Female drug-related deaths, 1990 to 2005
|
table |
| DRD |
Table DRD-2. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions
Part (iv) Total drug-related deaths under the age of 25 years, 1990 to 2005
|
table |
| DRD |
Table DRD-2. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions
Part (v) Totals and indexes, 1990 to 2005
|
table |
| DRD |
Table DRD-3. Number of acute drug-related deaths recorded in EU Member States, Norway and candidate countries according to EMCDDA standard definition 'Selection B', 1990 to 2005
|
table |
| DRD |
Table DRD-4. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to EMCDDA standard definition 'Selection D', 1990 to 2005
|
table |
| DRD |
Table DRD-5. Mortality due to drug-related deaths in European countries, in all adults and adults aged 15 to 39 years (total and males)
Part (i) Population mortality rates, 2005 or last year with available information
|
table |
| DRD |
Table DRD-5. Mortality due to drug-related deaths in European countries, in all adults and adults aged 15 to 39 years (total and males)
Part (ii) Proportional mortality due to drug-related deaths, 2005 or last year with available information
|
table |
| DRD |
Figure DRD-1. Reitox national reports 2006, taken from national mortality registries or special registries (forensic or police). Based on national definitions as presented in 2007 statistical bulletin, methodological notes for drug-related deaths
|
figure |
| DRD |
Figure DRD-2. Proportion of acute drug-related deaths occurring under the age of 25 years in 2003
|
figure |
| DRD |
Figure DRD-3. Trends in mean age of acute drug-related deaths in some of the EU-15 Member States, 1990 to 2005
|
figure |
| DRD |
Figure DRD-4. Trends in mean age of acute drug-related deaths in some new Member States of the EU 1990 to 2005
|
figure |
| DRD |
Figure DRD-5. lndexed trends in acute drug-related deaths and in the numbers of deaths under 25 years old
Part (i) Changes between 2000 and 2003
|
figure |
| DRD |
Figure DRD-5. lndexed trends in acute drug-related deaths and in the numbers of deaths under 25 years old
Part (ii) Indexed trend in the new Member States 1990-2005
|
figure |
| DRD |
Figure DRD-6. Indexed overall trends for males and females in acute drug-related deaths in the EU-15 member states and Norway, 1990 to 2005
|
figure |
| DRD |
Figure DRD-8. Indexed long term trend in acute drug-related deaths in the EU (old Member States and Norway), 1985 to 2005
|
figure |
| DRD |
Figure DRD-9. Trends in the proportion of drug-related deaths occurring under the age of 25 years old in the Member States 1990 to 2005 (three year moving average)
Part (i) Some EU countries and Norway, 1990 to 2005
|
figure |
| DRD |
Figure DRD-9. Trends in the proportion of drug-related deaths occurring under the age of 25 years old in the Member States 1990 to 2005 (three year moving average)
Part (ii) Some EU countries, 1990 to 2005
|
figure |
| DRD |
Figure DRD-9. Trends in the proportion of drug-related deaths occurring under the age of 25 years old in the Member States 1990 to 2005 (three year moving average)
Part (iii) Index in some Member States, 1985 to 2005
|
figure |
| DRD |
Figure DRD-10. Mean age of acute drug-related deaths in EU countries, last year with available data
|
figure |
| DRD |
Figure DRD-11. Indexed time series of patterns of acute drug-related death in different countries (according to general temporal patterns of evolution) and in the EU as a whole
Part (i) Index in some Member States, 1985 to 2005
|
figure |
| DRD |
Figure DRD-11. Indexed time series of patterns of acute drug-related death in different countries (according to general temporal patterns of evolution) and in the EU as a whole
Part (ii) Index in some Member States, 1985 to 2005
|
figure |
| DRD |
Figure DRD-11. Indexed time series of patterns of acute drug-related death in different countries (according to general temporal patterns of evolution) and in the EU as a whole
Part (iii) Index in some Member States, 1985 to 2005
|
figure |
| DRD |
Figure DRD-7. Proportional change in acute drug-related deaths in the EU Member States
Part (i) Changes between 2000 and 2003
|
figure |
| DRD |
Figure DRD-7. Proportional change in acute drug-related deaths in the EU Member States
Part (ii) Changes between 2003 and 2004/5
|
figure |
| DLO |
Table DLO-1. Number of reports for drug law offences. 1995 to 2005
|
table |
| DLO |
Table DLO-2. Offence types involved in reports for drug law offences: percentage of all reports for drug law offences
|
table |
| DLO |
Table DLO-3. Drug types involved in reports for drug law offences: percentage of all reports for drug law offences
|
table |
| DLO |
Table DLO-4. Number of drug law offences related to drug use or possession for use, 1999 to 2005
|
table |
| DLO |
Table DLO-5. Percentage of total drug law offences that are related to drug use or possession for use, 1996 to 2005
|
table |
| DLO |
Table DLO-6. Cannabis-related offences: as percentage of all drug law offences, 1996 to 2005
|
table |
| DLO |
Table DLO-7. Heroin-related offences as percentage of all drug law offences, 1996 to 2005
|
table |
| DLO |
Table DLO-8. Number of reports for drug law offences 1985 to 2005
|
table |
| DLO |
Figure DLO-1. Drug law offences in Europe, 2000-2005
Part (i) EU-15 Member States and Norway
|
figure |
| DLO |
Figure DLO-1. Drug law offences in Europe, 2000-2005
Part (ii) new EU Member States and Turkey
|
figure |
| DLO |
Figure DLO-2. Cannabis-related offences in Europe, 2000-2005
Part (i) EU-15 Member States and Norway
|
figure |
| DLO |
Figure DLO-2. Cannabis-related offences in Europe, 2000-2005
Part (ii) new EU Member States and Turkey
|
figure |
| DLO |
Figure DLO-3. Percentage of drug law offences for use or possession for use related to cannabis in Europe, 2000-2005
Part (i) EU-15 Member States and Norway
|
figure |
| DLO |
Figure DLO-3. Percentage of drug law offences for use or possession for use related to cannabis in Europe, 2000-2005
Part (ii) New Member States and Turkey
|
figure |
| DLO |
Figure DLO-4. Cocaine-related offences in Europe, 2000-2005
Part (i) EU-15 Member states and Norway
|
figure |
| DLO |
Figure DLO-4. Cocaine-related offences in Europe, 2000-2005
Part (ii) New EU Member States and Turkey
|
figure |
| DLO |
Figure DLO-5. Heroin-related offences in Europe, 2000-2005
Part (i) EU-15 Member States and Norway
|
figure |
| DLO |
Figure DLO-5. Heroin-related offences in Europe, 2000-2005
Part (ii) new EU Member States and Turkey
|
figure |
| DLO |
Figure DLO-6. Indexed trends in reports for drug law offences in EU member states 2000-2005
|
figure |
| TDI |
Table TDI-1. Data sources for data on clients entering treatment in 2005
|
table |
| TDI |
Table TDI-2. Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2005
Part (i) Total numbers of new clients entering treatment
|
table |
| TDI |
Table TDI-2. Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2005
Part (ii) Total numbers of all clients entering treatment
|
table |
| TDI |
Table TDI-2. Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2005
Part (iii) Numbers of treatment units covered for reporting clients entering treatment
|
table |
| TDI |
Table TDI-2. Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2005
Part (iv) Types of units covered for reporting clients entering treatment
|
table |
| TDI |
Table TDI-3. Distribution by primary drug used of new clients entering treatment, 1993 to 2005
Part (i) Percent of new clients using heroin
|
table |
| TDI |
Table TDI-3. Distribution by primary drug used of new clients entering treatment, 1993 to 2005
Part (ii) Percent of new clients using cocaine
|
table |
| TDI |
Table TDI-3. Distribution by primary drug used of new clients entering treatment, 1993 to 2005
Part (iii) Percent of new clients using cannabis
|
table |
| TDI |
Table TDI-3. Distribution by primary drug used of new clients entering treatment, 1993 to 2005
Part (iv) Percent of new clients using stimulants (amphetamines and MDMA)
|
table |
| TDI |
Table TDI-4. Characteristics of new clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available
Part (i) Demographics
|
table |
| TDI |
Table TDI-4. Characteristics of new clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available
Part (ii) Primary drug type used (percent of new clients using) and of those, the percent injecting it
|
table |
| TDI |
Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available
Part (i) Demographics of all clients entering treatment
|
table |
| TDI |
Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available
Part (ii) Primary drug type used by clients (percent of all clients) and of those, the percent injecting it
|
table |
| TDI |
Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available
Part (iii) Demographics of all men entering treatment
|
table |
| TDI |
Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available
Part (iv) Demographics of all women entering treatment
|
table |
| TDI |
Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available
Part (v) Primary drug type used by male clients (percent of all male clients)
|
table |
| TDI |
Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available
Part (vi) Primary drug type used by female clients (percent of all female clients)
|
table |
| TDI |
Table TDI-6. Incidence of treatment demands for drug use: new clients entering treatment in 2005 (rate per 100,000 population)
|
table |
| TDI |
Table TDI-7. Number of clients covered, number of outpatient and inpatient treatment centres covered and number of centres in the country in 2005 for countries supplying data
Part (i) Number of new and all clients entering treatment: by the treatment demand indicator schedule reports in 2005, by type of treatment centre
|
table |
| TDI |
Table TDI-7. Number of clients covered, number of outpatient and inpatient treatment centres covered and number of centres in the country in 2005 for countries supplying data
Part (ii) Outpatient treatment centres
|
table |
| TDI |
Table TDI-7. Number of clients covered, number of outpatient and inpatient treatment centres covered and number of centres in the country in 2005 for countries supplying data
Part (iii) Inpatient treatment centres
|
table |
| TDI |
Table TDI-8. New and all clients entering treatment for primary use of amphetamines, ecstasy and other non-cocaine stimulants in 2005 for countries supplying data
Part(i) All clients of all treatment centres reported for the country
|
table |
| TDI |
Table TDI-8. New and all clients entering treatment for primary use of amphetamines, ecstasy and other non-cocaine stimulants in 2005 for countries supplying data
Part(ii) New clients of all treatment centres reported for the country
|
table |
| TDI |
Table TDI-9. Clients entering outpatient treatment: mean age and gender distribution among new and all clients in 2005
|
table |
| TDI |
Table TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005
Part (i) Distribution of new outpatient clients by age group for each primary drug
|
table |
| TDI |
Table TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005
Part (ii) Distribution of new outpatient clients by primary drug for each age group
|
table |
| TDI |
Table TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005
Part (iii) Distribution of all outpatient clients by age group for each primary drug
|
table |
| TDI |
Table TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005
Part (iv) Distribution of all outpatient clients by primary drug for each age group
|
table |
| TDI |
Table TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005
Part (v) Distribution of new inpatient clients by age group for each primary drug
|
table |
| TDI |
Table TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005
Part (vi) Distribution of new inpatient clients by primary drug for each age group
|
table |
| TDI |
Table TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005
Part (vii) Distribution of all inpatient clients by age group for each primary drug
|
table |
| TDI |
Table TDI-10. Distribution of clients entering treatment according to age and primary drug - EU overall summary in 2005
Part (viii) Distribution of all inpatient clients by primary drug for each age group
|
table |
| TDI |
Table TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005
Part (i) Distribution of new outpatient clients by age group for each primary drug
|
table |
| TDI |
Table TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005
Part (ii) Distribution of new outpatient clients by primary drug for each age group
|
table |
| TDI |
Table TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005
Part (iii) Distribution of all outpatient clients by age group for each primary drug
|
table |
| TDI |
Table TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005
Part (iv) Distribution of all outpatient clients by primary drug for each age group
|
table |
| TDI |
Table TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005
Part (v) Distribution of new inpatient clients by age group for each primary drug
|
table |
| TDI |
Table TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005
Part (vi) Distribution of new inpatient clients by primary drug for each age group
|
table |
| TDI |
Table TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005
Part (vii) Distribution of all inpatient clients by age group for each primary drug
|
table |
| TDI |
Table TDI-11. Distribution of clients entering treatment according to age at first use of primary drug and primary drug - EU overall summary in 2005
Part (viii) Distribution of all inpatient clients by primary drug for each age group
|
table |
| TDI |
Table TDI-12. Distribution of educational level (percentage) of clients entering treatment in 2005 for countries reporting data
Part (i) New clients entering outpatient treatment
|
table |
| TDI |
Table TDI-12. Distribution of educational level (percentage) of clients entering treatment in 2005 for countries reporting data
Part (ii) All clients entering outpatient treatment
|
table |
| TDI |
Table TDI-12. Distribution of educational level (percentage) of clients entering treatment in 2005 for countries reporting data
Part (iii) New clients entering inpatient treatment
|
table |
| TDI |
Table TDI-12. Distribution of educational level (percentage) of clients entering treatment in 2005 for countries reporting data
Part (iv) All clients entering inpatient treatment
|
table |
| TDI |
Table TDI-13. Distribution (percentage) of labour status for clients entering treatment in 2005 for countries supplying data
Part (i) New clients entering outpatient treatment
|
table |
| TDI |
Table TDI-13. Distribution (percentage) of labour status for clients entering treatment in 2005 for countries supplying data
Part (ii) All clients entering outpatient treatment
|
table |
| TDI |
Table TDI-13. Distribution (percentage) of labour status for clients entering treatment in 2005 for countries supplying data
Part (iii) New clients entering inpatient treatment
|
table |
| TDI |
Table TDI-13. Distribution (percentage) of labour status for clients entering treatment in 2005 for countries supplying data
Part (iv) All clients entering inpatient treatment
|
table |
| TDI |
Table TDI-14. Distribution (percentage) by accomodation arrangements (persons with whom the client is living) of clients entering treatment in 2005 for countries reporting data
Part (i) New clients entering outpatient treatment
|
table |
| TDI |
Table TDI-14. Distribution (percentage) by accomodation arrangements (persons with whom the client is living) of clients entering treatment in 2005 for countries reporting data
Part (ii) All clients entering outpatient treatment
|
table |
| TDI |
Table TDI-14. Distribution (percentage) by accomodation arrangements (persons with whom the client is living) of clients entering treatment in 2005 for countries reporting data
Part (iii) New clients entering inpatient treatment
|
table |
| TDI |
Table TDI-14. Distribution (percentage) by accomodation arrangements (persons with whom the client is living) of clients entering treatment in 2005 for countries reporting data
Part (iv) All clients entering inpatient treatment
|
table |
| TDI |
Table TDI-15. Distribution (percentage) of living conditions of clients entering treatment in 2005 for countries reporting data
Part (i) New clients entering outpatient treatment
|
table |
| TDI |
Table TDI-15. Distribution (percentage) of living conditions of clients entering treatment in 2005 for countries reporting data
Part (ii) All clients entering outpatient treatment
|
table |
| TDI |
Table TDI-15. Distribution (percentage) of living conditions of clients entering treatment in 2005 for countries reporting data
Part (iii) New clients entering inpatient treatment
|
table |
| TDI |
Table TDI-15. Distribution (percentage) of living conditions of clients entering treatment in 2005 for countries reporting data
Part (iv) All clients entering inpatient treatment
|
table |
| TDI |
Table TDI-16. New clients entering outpatient treatment: distribution (percent) by source of referral in 2005 for countries supplying data
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005
Part (i) Percentage amongst new clients with opioids as primary drug
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005
Part (ii) Percentage amongst new clients with cocaine (HCl and crack) as primary drug
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005
Part (iii) Percentage amongst new clients with stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005
Part (iv) Percentage amongst new clients with hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005
Part (v) Percentage amongst all clients with opioids as primary drug
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005
Part (vi) Percentage amongst all clients with cocaine (HCl and crack) as primary drug
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005
Part (vii) Percentage amongst all clients with stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005
Part (viii) Percentage amongst all clients with hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2005
Part (i) Percentage distribution amongst new outpatient clients
|
table |
| TDI |
Table TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2005
Part (ii) Percentage distribution amongst all outpatient clients
|
table |
| TDI |
Table TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2005
Part (iii) Percentage distribution amongst new inpatient clients
|
table |
| TDI |
Table TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2005
Part (iv) Percentage distribution amongst all inpatient clients
|
table |
| TDI |
Table TDI-19. New and all clients entering outpatient and inpatient treatment: distribution (percentage) by primary drug at treatment in 2005 for those countries supplying data
Part (i) New clients entering outpatient treatment
|
table |
| TDI |
Table TDI-19. New and all clients entering outpatient and inpatient treatment: distribution (percentage) by primary drug at treatment in 2005 for those countries supplying data
Part (ii) All clients entering outpatient treatment
|
table |
| TDI |
Table TDI-19. New and all clients entering outpatient and inpatient treatment: distribution (percentage) by primary drug at treatment in 2005 for those countries supplying data
Part (iii) New clients entering inpatient treatment
|
table |
| TDI |
Table TDI-19. New and all clients entering outpatient and inpatient treatment: distribution (percentage) by primary drug at treatment in 2005 for those countries supplying data
Part (iv) All clients entering inpatient treatment
|
table |
| TDI |
Table TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2005 and in the general population
Part (i) New clients entering outpatient treatment
|
table |
| TDI |
Table TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2005 and in the general population
Part (ii) All clients entering outpatient treatment
|
table |
| TDI |
Table TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2005 and in the general population
Part (iii) New clients entering inpatient treatment
|
table |
| TDI |
Table TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2005 and in the general population
Part (iv) All clients entering inpatient treatment
|
table |
| TDI |
Table TDI-21. Gender ratio by primary drug - ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2005 for countries supplying data
Part (i) Gender ratio (ratio of males to females) among new clients entering outpatient treatment
|
table |
| TDI |
Table TDI-21. Gender ratio by primary drug - ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2005 for countries supplying data
Part (ii) Gender ratio (ratio of males to females) among all clients entering outpatient treatment
|
table |
| TDI |
Table TDI-21. Gender ratio by primary drug - ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2005 for countries supplying data
Part (iii) Gender ratio (ratio of males to females) among new clients entering inpatient treatment
|
table |
| TDI |
Table TDI-21. Gender ratio by primary drug - ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2005 for countries supplying data
Part (iv) Gender ratio (ratio of males to females) among all clients entering inpatient treatment
|
table |
| TDI |
Table TDI-22. Secondary drugs: number of citations by all clients in outpatient and inpatient centres in 2005: average for those EU countries supplying data
Part (i) Outpatient centres
|
table |
| TDI |
Table TDI-22. Secondary drugs: number of citations by all clients in outpatient and inpatient centres in 2005: average for those EU countries supplying data
Part (ii) Inpatient centres
|
table |
| TDI |
Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug
Part (i) Most frequent combination of the primary drug with the stated types of secondary drug (percentages)
|
table |
| TDI |
Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug
Part (ii) All clients with opioids as primary drug type: number of episodes reporting the stated drugs as secondary
|
table |
| TDI |
Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug
Part (iii) All clients with cocaine as primary drug type: number of episodes reporting the stated drugs as secondary
|
table |
| TDI |
Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug
Part (iv) All clients with cannabis as primary drug: number of episodes reporting the stated drug as secondary
|
table |
| TDI |
Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug
Part (v) All clients with stimulants other than cocaine as primary drug type: number of episodes reporting the stated drugs as secondary
|
table |
| TDI |
Table TDI-24. All and new clients entering outpatient and inpatient treatment centres by main drug for which they ask for treatment in 2005 for those countries supplying data
Part(i) All clients entering treatment by percentage of Outpatient and Inpatient treatment
|
table |
| TDI |
Table TDI-24. All and new clients entering outpatient and inpatient treatment centres by main drug for which they ask for treatment in 2005 for those countries supplying data
Part(ii) New clients entering treatment by percentage of Outpatient and Inpatient treatment
|
table |
| TDI |
Table TDI-25. Age distribution (column percentage) by gender among all clients entering outpatient treatment with primary drug: opioids, cocaine, stimulants and cannabis in 2005 for countries supplying data
|
table |
| TDI |
Table TDI-26. Number of all clients <15, 15-19, >19 years old by type of treatment centre and percentual (column) distribution in 2005 for countries supplying data
|
table |
| TDI |
Table TDI-27. All clients under 15, 15-19 and >19 entering treatment in 2005 for those countries supplying data
|
table |
| TDI |
Table TDI-28. Minor age groups: total number and percentage among all and new clients entering treatment in 2005
Part (i) percentage distribution of new clients by country
|
table |
| TDI |
Table TDI-29. Gender distrbution of all outpatient clients by three age groups in 2005 for those coutnries supplying data
|
table |
| TDI |
Table TDI-30. Trends in minors 1999 to 2005
Part (i) Number of all clients with age under 15
|
table |
| TDI |
Table TDI-30. Trends in minors 1999 to 2005
Part (iii) Number of all clients with age between 15 and 19
|
table |
| TDI |
Table TDI-30. Trends in minors 1999 to 2005
Part (iv) Percentage of all clients with age between 15 and 19
|
table |
| TDI |
Table TDI-30. Trends in minors 1999 to 2005
Part (v) Number of all clients with age more than 19
|
table |
| TDI |
Table TDI-30. Trends in minors 1999 to 2005
Part (vi) Percentage of all clients with age more than 19
|
table |
| TDI |
Table TDI-31. Gender ratio (male to female) in minors for those coutries supplying data for 2005
|
table |
| TDI |
Table TDI-101. Trends in gender distribution among new clients enering treatement from 1992 to 2005 (expressed as males / females ratio)
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (i) Number of clients using opioids as primary drug
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (ii) Number of clients using cocaine (HCl and 'crack') as primary drug
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (iv) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (v) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (vi) Number of clients using volatile/inhalants as primary drug
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (i) Number of clients using opioids as primary drug
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (ii) Number of clients using cocaine (HCl and 'crack') as primary drug
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (iv) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (v) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (vi) Number of clients using volatile inhalants as primary drug
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (i) Number of clients using opioids as primary drug
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (ii) Number of clients using cocaine (HCl and 'crack') as primary drug
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (iv) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (v) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (vi) Number of clients using volatile inhalants as primary drug
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (i) Number of clients using opioids as primary drug
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (ii) Number of clients using cocaine (HCl and 'crack') as primary drug
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (iv) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (v) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (vi) Number of clients using volatile inhalants as primary drug
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2005 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| |
.
|
|
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (i) Number of clients using opiates as primary drug
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (ii) Number of clients using cocaine as primary drug
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (iv) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (v) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (vi) Number of clients using volatile/inhalants as primary drug
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (i) Number of clients using opiates as primary drug
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (ii) Number of clients using cocaine as primary drug
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (iv) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (v) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (vi) Number of clients using volatile/inhalants as primary drug
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (i) Number of clients using opiates as primary drug
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (ii) Number of clients using cocaine as primary drug
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (iv) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (v) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (vi) Number of clients using volatile/inhalants as primary drug
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (i) Number of clients using opiates as primary drug
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (ii) Number of clients using cocaine as primary drug
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (iv) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (v) Number of clients using volatile/inhalants as primary drug
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (vi) Number of clients using volatile/inhalants as primary drug
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2005 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-110. Route of administration of cocaine HCl and crack as main reason for asking treatment among new and all outpatient clients in 2005
Part (i) Percentage amongst new clients with cocaine HCl as primary drug
|
table |
| TDI |
Table TDI-110. Route of administration of cocaine HCl and crack as main reason for asking treatment among new and all outpatient clients in 2005
Part (ii) Percentage amongst new clients with crack as primary drug
|
table |
| TDI |
Table TDI-110. Route of administration of cocaine HCl and crack as main reason for asking treatment among new and all outpatient clients in 2005
Part (iii) Percentage amongst all clients with cocaine HCl as primary drug
|
table |
| TDI |
Table TDI-110. Route of administration of cocaine HCl and crack as main reason for asking treatment among new and all outpatient clients in 2005
Part (iv) Percentage amongst all clients with crack as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005
Part (i) Percentage distribution amongst new clients with opioids as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005
Part (ii) Percentage distribution amongst all clients with opioids as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005
Part (iii) Percentage distribution amongst new clients with cannabis as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005
Part (iv) Percentage distribution amongst all clients with cannabis as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005
Part (v) Percentage distribution amongst new clients with amphetamines and MDMA as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005
Part (vi) Percentage distribution amongst all clients with amphetamines and MDMA as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005
Part (vii) Percentage distribution amongst new clients with cocaine as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2005
Part (viii) Percentage distribution amongst all clients with cocaine as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005
Part (i) Percentage distribution amongst new clients with opioids as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005
Part (ii) Percentage distribution amongst all clients with opioids as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005
Part (iii) Percentage distribution amongst new clients with cannabis as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005
Part (iv) Percentage distribution amongst all clients with cannabis as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005
Part (v) Percentage distribution amongst new clients with amphetamines and MDMA as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005
Part (vi) Percentage distribution amongst all clients with amphetamines and MDMA as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005
Part (vii) Percentage distribution amongst new clients with cocaine as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2005
Part (viii) Percentage distribution amongst all clients with cocaine as primary drug
|
table |
| TDI |
Table TDI-113. New and all clients entering outpatient treatment for primary use of amphetamines, ecstasy and other stimulants in 2005 for countries supplying data
Part(i) New clients
|
table |
| TDI |
Table TDI-113. New and all clients entering outpatient treatment for primary use of amphetamines, ecstasy and other stimulants in 2005 for countries supplying data
Part(ii) All clients
|
table |
| TDI |
Table TDI-114. All and new clients entering treatment for opioids by type of opioid misused for countries supplying data in 2005
Part(i) Percentage among all clients entering treatment for opioids use from all clients entering treatment
|
table |
| TDI |
Table TDI-114. All and new clients entering treatment for opioids by type of opioid misused for countries supplying data in 2005
Part (ii) Percentage among new clients entering treatment for opioids use from all new clients entering treatment
|
table |
| TDI |
Table TDI-114. All and new clients entering treatment for opioids by type of opioid misused for countries supplying data in 2005
Part (iii) Number and percentage among all clients entering treatment
|
table |
| TDI |
Table TDI-114. All and new clients entering treatment for opioids by type of opioid misused for countries supplying data in 2005
Part(iv) Number and percentage among new client entering treatment
|
table |
| TDI |
Table TDI-115. New and all clients entering treatment for primary use of cocaine HCl and crack in 2005 for countries supplying data
Part (i) Among all clients entering outpatient treatment
|
table |
| TDI |
Table TDI-115. New and all clients entering treatment for primary use of cocaine HCl and crack in 2005 for countries supplying data
Part (ii) Among new clients entering outpatient treatment
|
table |
| TDI |
Table TDI-115. New and all clients entering treatment for primary use of cocaine HCl and crack in 2005 for countries supplying data
Part (iii) Among all clients entering treatment (all types of treatment)
|
table |
| TDI |
Table TDI-115. New and all clients entering treatment for primary use of cocaine HCl and crack in 2005 for countries supplying data
Part (iv) Among new clients entering treatment (all types of treatment)
|
table |
| TDI |
Table TDI-116. Secondary drug distribution among all clients entering outpatient treatment with primary drug: amphetamines and ecstasy in 2005 for countries supplying data
|
table |
| TDI |
Table TDI-117. Mean age of all clients entering outpatient and inpatient treatment for amphetamines and ecstasy for countries supplying data in 2005
|
table |
| TDI |
Table TDI-118. Polydrug use with cocaine among all clients entering outpatient treatment, for countries supplying data for 2005
Part (i) Combination of the primary drug with the stated types of secondary drug (percentages) - overall / EU summary
|
table |
| TDI |
Table TDI-118. Polydrug use with cocaine among all clients entering outpatient treatment, for countries supplying data for 2005
Part (ii) All clients with cocaine HCl as primary drug type: numbers of episodes reporting the stated drugs as secondary
|
table |
| TDI |
Table TDI-118. Polydrug use with cocaine among all clients entering outpatient treatment, for countries supplying data for 2005
Part (iii) All clients with crack as primary drug type: number of episodes reporting the stated drugs as secondary
|
table |
| TDI |
Table TDI-118. Polydrug use with cocaine among all clients entering outpatient treatment, for countries supplying data for 2005
Part (iv) All clients with opioids as primary drug type: number of episodes reporting cocaine HCl and crack as secondary
|
table |
| TDI |
Table TDI-119. Percentage proportion of all clients treated on opioid misuse from all treated clients within the treatment centres by type of treatment centre for countries supplying data in 2005
|
table |
| TDI |
Table TDI-120. Mean age and gender ratio (males to females) among all clients entering outpatient treatment centres in 2005 for those countries supplying data
|
table |
| TDI |
Table TDI-121. Frequency of use of primary drug: cocain HCl and crack among all outpatient clients in 2005 for countries supplying data
|
table |
| TDI |
Table TDI-122. All outpatient clients under 15 entering treatment by primary drug in 2005 for those countries supplying data
|
table |
| TDI |
Table TDI-123. All drug clients under 15 entering drug treatment in 2005 in 6 EU countries + Turkey
|
table |
| TDI |
Table TDI-124. All drug clients under 15 by year of age entering drug treatment in 2005 in 6 EU countries + Turkey
|
table |
| TDI |
Table TDI-125. Primary drug of consumption among all drug clients under 15 entering drug treatment in 2005 in 6 EU countries + Turkey
|
table |
| TDI |
Figure TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 1999 to 2005
Part (i) Trend in distribution by primary drug (percentage)
|
figure |
| TDI |
Figure TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 1999 to 2005
Part (ii) Trend in numbers of clients by primary drug
|
figure |
| TDI |
Figure TDI-3. Estimated numbers of all clients asking treatment by heroin, cocaine, cannabis, other stimulants (percent): overall EU trend in from 1999 to 2005
Part (i) Trend in percentages of clients by primary drug
|
figure |
| TDI |
Figure TDI-3. Estimated numbers of all clients asking treatment by heroin, cocaine, cannabis, other stimulants (percent): overall EU trend in from 1999 to 2005
Part (ii) Trend in numbers of clients by primary drug
|
figure |
| TDI |
Figure TDI-2. New and all clients entering treatment in 2005 by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs (21 countries- 20 EU + TR - included for all clients and 22 countries - 21 EU + TK - for new clients)
|
figure |
| TDI |
Figure TDI-5. Trends in cocaine and in the total number of new clients from 1999 to 2005 in 20 countries
|
figure |
| TDI |
Figure TDI-6. New and all outpatient clients by age group in 2005 for those countries supplying data
|
figure |
| TDI |
Figure TDI-7. Distribution according to primary drug of all clients aged under 15 entering treatment - EU summary for countries supplying data in 2005
|
figure |
| TDI |
Figure TDI-8. Age distribution of all clients 10-14 years entering treatment for cannabis and volatile/inhalant drugs - EU overall summary for countries supplying data in 2005
|
figure |
| TDI |
Figure TDI-9. New treatment demand for drug use: (rate per 100,000 population in 2006) and reporting coverage of treatment centers
|
figure |
| TDI |
Figure TDI-10. Percentage of clients injecting opoids and cocaine among all outpatient clients by country in 2005
|
figure |
| TDI |
Figure TDI-11. Numbers of clients reported entering treatment for any drug: overall EU trends by age group for all clients entering treatment 1999-2005
|
figure |
| TDI |
Figure TDI-12. Gender ratio of all outpatient clients by three age groups in 2005: overall EU
|
figure |
| TDI |
Figure TDI-13. Distribution of all clients entering treatment by primary drug at treatment in 2005 or most recent year available
|
figure |
| TDI |
Figure TDI-14. Percent using cocaine as primary drug among new clients entering treatment, 1993 to 2005 - countries reporting in excess of 5% of new clients
|
figure |
| TDI |
Figure TDI-4. Male to female ratio among all clients entering outpatient treatment by main drug in 2005
|
figure |
| GPS |
Figure GPS-12. Last year prevalence of cannabis by age group in some Member States, measured by national population surveys – last survey available
Part (ii) Last year prevalence in some new EU Member States
|
figure |
| HSR |
Figure HSR-2. Clients in substitution treatment per 100.000 adult population (2003 - 2005)
|
figure |
| TDI |
Table TDI-28. Minor age groups: total number and percentage among all and new clients entering treatment in 2005
Part (ii) percentage distribution of all clients by country
|
table |
| TDI |
Table TDI-30. Trends in minors 1999 to 2005
Part (ii) Percentage of all clients with age under 15
|
table |
| PDU |
Table PDU-5. Studies used in focused analysis of proportions of young (aged less than 25 years) and new (injecting for less than 2 years) IDUs among samples tested for infectious diseases
Part (i) Summary of prevalence studies in IDUs with available data on distribution by age
|
table |
| PDU |
Table PDU-5. Studies used in focused analysis of proportions of young (aged less than 25 years) and new (injecting for less than 2 years) IDUs among samples tested for infectious diseases
Part (ii) Summary of prevalence studies in IDUs with available data on distribution by years of injecting
|
table |
| DRD |
Table DRD-6. Methodological features of drug-related deaths reported by National Reitox Focal Points (Based on national definitions - Reitox Standard Table 5 Part 1)
|
table |
| DRD |
Table DRD-7. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions
Part (i) Total drug-related deaths, 1985 to 2005
|
table |
| DRD |
Table DRD-7. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions
Part (ii) Totals and indexes, 1985 to 2005
|
table |
